Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia

Cristiana O’Brien, Nirvana Nursimulu, Anit Tyagi, Rachel Culp-Hill, Andrea Arruda, Tracy Murphy, Mark D. Minden, Andrew Kent, Brett Stevens, Daniel A. Pollyea, Kristin Hope, Sushant Kumar, Julie A. Reisz, Angelo D'Alessandro, Courtney L. Jones

Blood (2025) 146 (21): 2589–2596.

https://doi.org/10.1182/blood.2025029132

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting nicotinamide salvage pathway is a unique metabolic vulnerability of high-risk MDS stem cells

Blood (2025) 146 (Supplement 1): 232.

https://doi.org/10.1182/blood-2025-232

Published: 2025

Journal Articles

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

Daniel Peters, Diana Abbott, Jingjing Zhang, Jacob Fang, Zenggang Pan, Jeffrey Schowinsky, Jonathan Gutman, Andrew Kent, Mathew Angelos, Christine McMahon, Maria Amaya, Marc Schwartz, Wei Xie, Jonathan Galeotti, Jill Buss, Ann-Kathrin Eisfeld, Curtis Lachowiez, Joshua Zeidner, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2025-3377

Published: 2025

Journal Articles

Next-generation sequencing (NGS) of DNA isolated from nail specimens and run in parallel with tumor NGS accurately and efficiently detects germline predisposition variants in myeloid malignancies

Meredith Beaton, Michelle Springer, Cailin Collins, Mathew Angelos, Andrew Kent, Maria Amaya, Jonathan Gutman, Marc Schwartz, Danica Wiredja, Michael Clay, Alisa Gaskell, Nicholas Willard, Daniel Pollyea, Christine McMahon

Blood (2025) 146 (Supplement 1): 1084.

https://doi.org/10.1182/blood-2025-1084

Published: 2025

Journal Articles

Patients with AML with an IDH2 R172K mutation have improved overall survival with venetoclax + azacitidine as compared to those with IDH2 R140Q mutations

Allyson Freedy, Danica Wiredja, Jingjing Zhang, Christine McMahon, Mathew Angelos, Maria Amaya, Jonathan Gutman, Marc Schwartz, Daniel Pollyea, Andrew Kent

Blood (2025) 146 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2025-7018

Published: 2025

Journal Articles

The impact of monocytic phenotype and NPM1-mutation status in Acute Myeloid Leukemia when treated with traditional induction chemotherapy compared to azacitidine and venetoclax

Michael Jones, Cailin Collins, Danica Wiredja, Jingjing Zhang, Christine McMahon, Mathew Angelos, Maria Amaya, Jonathan Gutman, Marc Schwartz, Daniel Pollyea, Andrew Kent

Blood (2025) 146 (Supplement 1): 3478.

https://doi.org/10.1182/blood-2025-3478

Published: 2025

Journal Articles

RNA fusion sequencing identifies clinically relevant and novel fusions with therapeutic implications in adults with Acute Myeloid Leukemia (AML)

Christine McMahon, Mathew Angelos, Andrew Kent, Maria Amaya, Marc Schwartz, Jonathan Gutman, Michael Clay, Danica Wiredja, Nicholas Willard, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 5287.

https://doi.org/10.1182/blood-2025-5287

Published: 2025

Journal Articles

UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial

Marc Schwartz, Navin Pinto, Michael Verneris, Daniel Pollyea, Christine McMahon, Jonathan Gutman, Angela Ohm, Maria Amaya, Andrew Kent, Mathew Angelos, Cheri Adams, Bonnie Yates, Katie Anttila, Jessica Dell-Martin, Kimberly Jordan, Terry Fry

Blood (2025) 146 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2025-4165

Published: 2025

Journal Articles

Treatment-Related and De Novo Ccus Have Similar Molecular Features and Risk of Progression to Myeloid Malignancies

Jennifer Santos, Diana Abbott, Grace Bosma, Andrew Kent, Marc Schwartz, Christine M. McMahon, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

Blood (2024) 144 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2024-201062

Published: 2024

Journal Articles

Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Jason S. Gilbert, Megan Connor, Grace Bosma, Christine M. McMahon, Maria L Amaya, Jonathan Gutman, Marc Schwartz, Andrew Kent, Diana Abbott, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2024-199862

Published: 2024

Journal Articles

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

Cassandra Duarte, Diana Abbott, Christine M. McMahon, Andrew Kent, Marc Schwartz, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

Blood (2024) 144 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2024-201061

Published: 2024

Journal Articles

Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia

Jason S. Gilbert, Andrew Kent, Jonathan Gutman, Maria L Amaya, Christine M. McMahon, Daniel A Pollyea, Marc Schwartz

Blood (2024) 144 (Supplement 1): 7280.

https://doi.org/10.1182/blood-2024-200993

Published: 2024

Journal Articles

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Blood (2024) 144 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2024-199336

Published: 2024

Journal Articles

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan Gutman, Andrew Kent, Diana Abbott, Connor Sohalski, Jessica Dell-Martin, Ayele Belachew, Brett M Stevens, Craig T Jordan, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2024-202839

Published: 2024

Journal Articles

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 969.

https://doi.org/10.1182/blood-2024-199267

Published: 2024

Journal Articles

Outcomes of Haplo-Cord and Dual-Cord Transplants: A Single-Center Retrospective Analysis

Michael K Jones, Andrew Kent, Kellen Gil, Enkhtsetseg Purev, Bradley M. Haverkos, Marc Schwartz, Christine M. McMahon, Maria L Amaya, Grace N Bosma, Rachel Rabinovitch, Daniel A. Pollyea, Jonathan A Gutman

Blood (2023) 142 (Supplement 1): 7084.

https://doi.org/10.1182/blood-2023-190558

Published: 2023

Journal Articles

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Blood (2022) 140 (Supplement 1): 3275–3276.

https://doi.org/10.1182/blood-2022-157802

Published: 2022

Journal Articles

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Blood (2021) 138 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2021-154151

Published: 2021

Journal Articles

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Andrew Kent, MD PhD, Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138832

Published: 2020

Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 1311.

https://doi.org/10.1182/blood-2019-127418

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia

Targeting nicotinamide salvage pathway is a unique metabolic vulnerability of high-risk MDS stem cells

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

Next-generation sequencing (NGS) of DNA isolated from nail specimens and run in parallel with tumor NGS accurately and efficiently detects germline predisposition variants in myeloid malignancies

Patients with AML with an IDH2 R172K mutation have improved overall survival with venetoclax + azacitidine as compared to those with IDH2 R140Q mutations

The impact of monocytic phenotype and NPM1-mutation status in Acute Myeloid Leukemia when treated with traditional induction chemotherapy compared to azacitidine and venetoclax

RNA fusion sequencing identifies clinically relevant and novel fusions with therapeutic implications in adults with Acute Myeloid Leukemia (AML)

UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial

Treatment-Related and De Novo Ccus Have Similar Molecular Features and Risk of Progression to Myeloid Malignancies

Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Outcomes of Haplo-Cord and Dual-Cord Transplants: A Single-Center Retrospective Analysis

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only